(Q34196799)

31 July 2017

1 reference

title

Oxazolidinone structure-activity relationships leading to linezolid (English)

1 reference

31 July 2017

Oxazolidinone Structure–Activity Relationships Leading to Linezolid (English)

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

2 January 2024

1 reference

Michael R. Barbachyn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746812

2 January 2024

Charles W. Ford

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746812

2 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

31 July 2017

9 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12746812

full work available at URL

2 January 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fanie.200200528

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

https://onlinelibrary.wiley.com/doi/pdf/10.1002/anie.200200528

2 January 2024

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Angewandte Chemie International Edition

2 January 2024

published in

0 references

volume

42

1 reference

31 July 2017

issue

18

1 reference

31 July 2017

page(s)

2010-2023

1 reference

Antimicrobial Agents and Chemotherapy

31 July 2017

cites work

1

36

1791

Murray B. E.

1987

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

World-wide development of antibiotic resistance in pneumococci

2 January 2024

2

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

2 January 2024

4

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

2 January 2024

5

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study

2 January 2024

6

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

International recognition of methicillin-resistant strains of Staphylococcus aureus

2 January 2024

7

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

2 January 2024

8

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents

2 January 2024

9

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

2 January 2024

10

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

2 January 2024

11

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis

2 January 2024

12

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group

2 January 2024

18

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives

2 January 2024

21

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones

2 January 2024

33

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics

2 January 2024

36

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Structure-activity relationships of the fluoroquinolones

2 January 2024

37

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

2 January 2024

44

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

2 January 2024

45

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

2 January 2024

48

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

2 January 2024

49

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

2 January 2024

50

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

2 January 2024

51

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

2 January 2024

52

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

2 January 2024

53

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

2 January 2024

54

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

2 January 2024

55

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria

2 January 2024

56

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

2 January 2024

58

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Efficacy of linezolid in experimental otitis media

2 January 2024

60

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Efficacy of linezolid in a staphylococcal endocarditis rabbit model

2 January 2024

62

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

2 January 2024

63

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

2 January 2024

69

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

2 January 2024

70

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

2 January 2024

71

1 reference

https://api.crossref.org/works/10.1002/ANIE.200200528

2 January 2024

Identifiers

1 reference

release_danij4j7irhvxnpxbqdpnmh7q4

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/danij4j7irhvxnpxbqdpnmh7q4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference